{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:12:32Z","timestamp":1793243552692,"version":"4.5.0"},"reference-count":114,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2020,12,1]]},"DOI":"10.1001\/jamaoncol.2020.4600","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T15:50:43Z","timestamp":1602172243000},"page":"1890","source":"Crossref","is-referenced-by-count":396,"title":["Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia"],"prefix":"10.1001","volume":"6","author":[{"given":"Nicholas J.","family":"Short","sequence":"first","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouhao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenqi","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald A.","family":"Berry","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie D.","family":"Freeman","sequence":"additional","affiliation":[{"name":"Institute of Infection and Immunity, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Hourigan","sequence":"additional","affiliation":[{"name":"Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Nogueras Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunsoo","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"coi200074r1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia.","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"issue":"10147","key":"coi200074r2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia.","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"issue":"23","key":"coi200074r3","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia.","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"coi200074r4","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"4","key":"coi200074r5","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"8","key":"coi200074r6","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nrclinonc.2013.100","article-title":"Minimal residual disease in acute myeloid leukaemia.","volume":"10","author":"Hourigan","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"coi200074r7","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"10","key":"coi200074r8","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia.","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"coi200074r9","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.","volume":"30","author":"B\u00f6ttcher","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi200074r10","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","article-title":"Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.","volume":"107","author":"Br\u00fcggemann","year":"2006","journal-title":"Blood"},{"issue":"18","key":"coi200074r11","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","article-title":"Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).","volume":"113","author":"Bassan","year":"2009","journal-title":"Blood"},{"issue":"7","key":"coi200074r12","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis.","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"issue":"4","key":"coi200074r13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1470-2045(15)70082-3","article-title":"Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.","volume":"16","author":"Pui","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"coi200074r14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","article-title":"Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.","volume":"14","author":"Vora","year":"2013","journal-title":"Lancet Oncol"},{"issue":"5","key":"coi200074r15","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis.","volume":"102","author":"Buckley","year":"2017","journal-title":"Haematologica"},{"issue":"31","key":"coi200074r16","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","article-title":"High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study.","volume":"31","author":"Terwijn","year":"2013","journal-title":"J Clin Oncol"},{"issue":"32","key":"coi200074r17","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2013.49.1753","article-title":"Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.","volume":"31","author":"Freeman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi200074r18","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML.","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"coi200074r19","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/cncr.30361","article-title":"Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.","volume":"123","author":"Ravandi","year":"2017","journal-title":"Cancer"},{"issue":"2","key":"coi200074r20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","article-title":"Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the Acute Leukemia French Association Group.","volume":"35","author":"Balsat","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15","key":"coi200074r21","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","article-title":"Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations.","volume":"36","author":"Freeman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"13","key":"coi200074r22","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia.","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"coi200074r23","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.3324\/haematol.2018.208454","article-title":"How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?","volume":"104","author":"Short","year":"2019","journal-title":"Haematologica"},{"issue":"7","key":"coi200074r24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement.","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"9","key":"coi200074r25","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1172\/JCI91964","article-title":"Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse.","volume":"127","author":"Parkin","year":"2017","journal-title":"J Clin Invest"},{"key":"coi200074r26","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2013.71","article-title":"BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia.","volume":"4","author":"Weber","year":"2014","journal-title":"Blood Cancer J"},{"issue":"5","key":"coi200074r27","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/bjh.14343","article-title":"Feasibility of BAALC gene expression for detection of minimal residual disease and risk stratification in normal karyotype acute myeloid leukaemia.","volume":"175","author":"Weber","year":"2016","journal-title":"Br J Haematol"},{"issue":"6","key":"coi200074r28","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1158\/1078-0432.CCR-14-1999","article-title":"Prospective validation of a new method of monitoring minimal residual disease in childhood acute myelogenous leukemia.","volume":"21","author":"Steinbach","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"coi200074r29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"coi200074r30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrd1927","article-title":"Bayesian clinical trials.","volume":"5","author":"Berry","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"coi200074r35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"22","key":"coi200074r36","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2014.55.2208","article-title":"Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.","volume":"32","author":"Uno","year":"2014","journal-title":"J Clin Oncol"},{"issue":"15","key":"coi200074r37","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1200\/JCO.2015.64.2488","article-title":"Comparison of treatment effects measured by the hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials.","volume":"34","author":"Trinquart","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi200074r38","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood.V98.6.1746","article-title":"Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification.","volume":"98","author":"San Miguel","year":"2001","journal-title":"Blood"},{"issue":"9","key":"coi200074r39","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2002-10-3064","article-title":"Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children\u2019s Cancer Group study of 252 patients with acute myeloid leukemia.","volume":"101","author":"Sievers","year":"2003","journal-title":"Blood"},{"issue":"2","key":"coi200074r40","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1046\/j.1365-2141.2003.04610.x","article-title":"Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia.","volume":"123","author":"Coustan-Smith","year":"2003","journal-title":"Br J Haematol"},{"issue":"8","key":"coi200074r41","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/sj.leu.2403405","article-title":"MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia.","volume":"18","author":"Feller","year":"2004","journal-title":"Leukemia"},{"issue":"8","key":"coi200074r42","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/sj.leu.2403809","article-title":"Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia.","volume":"19","author":"Weisser","year":"2005","journal-title":"Leukemia"},{"issue":"7","key":"coi200074r43","first-page":"881","article-title":"Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy.","volume":"90","author":"Weisser","year":"2005","journal-title":"Haematologica"},{"issue":"1","key":"coi200074r44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.leu.2404015","article-title":"Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].","volume":"20","author":"Perea","year":"2006","journal-title":"Leukemia"},{"issue":"10","key":"coi200074r45","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1200\/JCO.2005.03.5303","article-title":"High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.","volume":"24","author":"Lapillonne","year":"2006","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi200074r46","first-page":"833","article-title":"The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy.","volume":"91","author":"Laane","year":"2006","journal-title":"Haematologica"},{"issue":"22","key":"coi200074r47","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1200\/JCO.2005.05.4312","article-title":"Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.","volume":"24","author":"Langebrake","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi200074r48","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3324\/haematol.10432","article-title":"Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.","volume":"92","author":"Maurillo","year":"2007","journal-title":"Haematologica"},{"issue":"2","key":"coi200074r49","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12185-008-0108-1","article-title":"Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan.","volume":"88","author":"Narimatsu","year":"2008","journal-title":"Int J Hematol"},{"issue":"2","key":"coi200074r50","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/cyto.b.20444","article-title":"The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.","volume":"76","author":"Al-Mawali","year":"2009","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"coi200074r51","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3324\/haematol.13110","article-title":"Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia.","volume":"94","author":"Hess","year":"2009","journal-title":"Haematologica"},{"issue":"31","key":"coi200074r52","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1200\/JCO.2009.22.4865","article-title":"Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.","volume":"27","author":"Cilloni","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi200074r53","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/leu.2010.112","article-title":"Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience.","volume":"24","author":"Gui\u00e8ze","year":"2010","journal-title":"Leukemia"},{"issue":"13","key":"coi200074r54","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2009-12-258178","article-title":"Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia.","volume":"116","author":"Buccisano","year":"2010","journal-title":"Blood"},{"issue":"23","key":"coi200074r55","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1200\/JCO.2010.28.6468","article-title":"Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.","volume":"28","author":"Corbacioglu","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"coi200074r56","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/leu.2010.153","article-title":"Clinical significance of flow cytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97\/MRC AML12 protocol.","volume":"24","author":"van der Velden","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"coi200074r57","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/annonc\/mdq402","article-title":"Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information.","volume":"22","author":"Chou","year":"2011","journal-title":"Ann Oncol"},{"issue":"2","key":"coi200074r58","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2010.020","article-title":"Clinical analysis and optimization of postremission therapy for acute myeloid leukemia patients with minimal residual disease as determined by flow cytometry.","volume":"2","author":"Inoue","year":"2010","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"19","key":"coi200074r59","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","article-title":"Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.","volume":"29","author":"Kr\u00f6nke","year":"2011","journal-title":"J Clin Oncol"},{"issue":"18","key":"coi200074r60","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1200\/JCO.2010.34.2873","article-title":"Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation.","volume":"29","author":"Chen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi200074r61","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.leukres.2011.09.005","article-title":"WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation.","volume":"36","author":"Gray","year":"2012","journal-title":"Leuk Res"},{"issue":"4","key":"coi200074r62","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1751-553X.2012.01416.x","article-title":"Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia.","volume":"34","author":"Terwijn","year":"2012","journal-title":"Int J Lab Hematol"},{"issue":"8","key":"coi200074r63","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2012-02-408336","article-title":"Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children\u2019s Oncology Group.","volume":"120","author":"Loken","year":"2012","journal-title":"Blood"},{"issue":"14","key":"coi200074r64","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1182\/blood-2012-06-435669","article-title":"Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.","volume":"120","author":"Yin","year":"2012","journal-title":"Blood"},{"issue":"29","key":"coi200074r65","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1200\/JCO.2011.41.5323","article-title":"Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.","volume":"30","author":"Inaba","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi200074r66","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.leukres.2012.11.002","article-title":"Prognostic significance of flow cytometric minimal residual disease assessment after the first induction course in Chinese childhood acute myeloid leukemia.","volume":"37","author":"Xu","year":"2013","journal-title":"Leuk Res"},{"issue":"12","key":"coi200074r67","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","article-title":"Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.","volume":"121","author":"Jourdan","year":"2013","journal-title":"Blood"},{"issue":"6","key":"coi200074r68","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1007\/s12185-013-1344-6","article-title":"Monitoring of minimal residual disease in acute myeloid leukemia with t(8;21)(q22;q22).","volume":"97","author":"Zhang","year":"2013","journal-title":"Int J Hematol"},{"issue":"3","key":"coi200074r69","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/ejh.12130","article-title":"Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.","volume":"91","author":"Hoyos","year":"2013","journal-title":"Eur J Haematol"},{"issue":"1","key":"coi200074r70","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood-2012-10-461749","article-title":"The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML.","volume":"122","author":"Shayegi","year":"2013","journal-title":"Blood"},{"issue":"12","key":"coi200074r71","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.leukres.2013.07.005","article-title":"Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia.","volume":"37","author":"Marani","year":"2013","journal-title":"Leuk Res"},{"issue":"7","key":"coi200074r72","first-page":"1149","article-title":"Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: a comparison between multiparameter flow cytometry and Wilm\u2019s tumor 1 levels.","volume":"93","author":"Rossi","year":"2014","journal-title":"Ann Hematol"},{"issue":"8","key":"coi200074r73","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2014.104133","article-title":"Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.","volume":"99","author":"Hubmann","year":"2014","journal-title":"Haematologica"},{"issue":"10","key":"coi200074r74","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s00277-014-2107-z","article-title":"High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).","volume":"93","author":"Wang","year":"2014","journal-title":"Ann Hematol"},{"issue":"2","key":"coi200074r75","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/leu.2014.186","article-title":"Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.","volume":"29","author":"K\u00f6hnke","year":"2015","journal-title":"Leukemia"},{"issue":"10","key":"coi200074r76","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/pbc.25109","article-title":"Monitoring the AML1\/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia.","volume":"61","author":"Zhang","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"coi200074r77","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.leukres.2014.05.021","article-title":"Interest of cytogenetic and FISH evaluation for prognosis evaluation in 198 patients with acute myeloid leukemia in first complete remission in a single institution.","volume":"38","author":"Hirsch","year":"2014","journal-title":"Leuk Res"},{"issue":"15","key":"coi200074r78","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.18632\/oncotarget.2196","article-title":"MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.","volume":"5","author":"Lambert","year":"2014","journal-title":"Oncotarget"},{"issue":"12","key":"coi200074r79","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1038\/bmt.2014.180","article-title":"Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.","volume":"49","author":"Yoon","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"coi200074r80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107587","article-title":"Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.","volume":"9","author":"Terwijn","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"coi200074r81","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.3324\/haematol.2014.114579","article-title":"Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement.","volume":"100","author":"Pigazzi","year":"2015","journal-title":"Haematologica"},{"issue":"11","key":"coi200074r82","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1200\/JCO.2014.58.3518","article-title":"Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.","volume":"33","author":"Chen","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"coi200074r83","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00277-015-2364-5","article-title":"Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients.","volume":"94","author":"Buccisano","year":"2015","journal-title":"Ann Hematol"},{"issue":"6","key":"coi200074r84","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.leukres.2015.03.021","article-title":"The association of level of reduction of Wilms\u2019 tumor gene 1 mRNA transcript in bone marrow and outcome in acute myeloid leukemia patients.","volume":"39","author":"Shibasaki","year":"2015","journal-title":"Leuk Res"},{"issue":"8","key":"coi200074r85","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.2015.9643","article-title":"Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia.","volume":"314","author":"Klco","year":"2015","journal-title":"JAMA"},{"issue":"3","key":"coi200074r86","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/leu.2015.255","article-title":"Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.","volume":"30","author":"Zeijlemaker","year":"2016","journal-title":"Leukemia"},{"key":"coi200074r87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2015.10.002","article-title":"Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia.","volume":"40","author":"Vidriales","year":"2016","journal-title":"Leuk Res"},{"issue":"3","key":"coi200074r88","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3324\/haematol.2015.131946","article-title":"Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.","volume":"101","author":"Willekens","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"coi200074r89","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/cam4.593","article-title":"Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.","volume":"5","author":"Malagola","year":"2016","journal-title":"Cancer Med"},{"issue":"4","key":"coi200074r90","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s12185-016-1937-y","article-title":"Residual disease detected by multidimensional flow cytometry shows prognostic significance in childhood acute myeloid leukemia with intermediate cytogenetics and negative FLT3-ITD: a report from the Tokyo Children\u2019s Cancer Study Group.","volume":"103","author":"Keino","year":"2016","journal-title":"Int J Hematol"},{"key":"coi200074r91","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.61","article-title":"Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length.","volume":"5","author":"Kim","year":"2015","journal-title":"Blood Cancer J"},{"issue":"4","key":"coi200074r92","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bjh.14093","article-title":"Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study.","volume":"174","author":"Tierens","year":"2016","journal-title":"Br J Haematol"},{"issue":"10","key":"coi200074r93","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1038\/leu.2016.120","article-title":"Effect of measurable (\u201cminimal\u201d) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.","volume":"30","author":"Othus","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"coi200074r94","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/leu.2016.177","article-title":"Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group.","volume":"31","author":"Manara","year":"2017","journal-title":"Leukemia"},{"key":"coi200074r95","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.12659\/MSM.900429","article-title":"Prognostic significance of mixed-lineage leukemia (MLL) gene detected by real-time fluorescence quantitative PCR assay in acute myeloid leukemia.","volume":"22","author":"Huang","year":"2016","journal-title":"Med Sci Monit"},{"issue":"1","key":"coi200074r96","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/bjh.14523","article-title":"Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002\/01 study protocol.","volume":"177","author":"Buldini","year":"2017","journal-title":"Br J Haematol"},{"issue":"4","key":"coi200074r97","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bjh.14635","article-title":"Wilms tumor 1 gene expression levels improve risk stratification in AML patients: results of a multicentre study within the Spanish Group for Molecular Biology in Haematology.","volume":"181","author":"Mart\u00ednez-Laperche","year":"2018","journal-title":"Br J Haematol"},{"issue":"10","key":"coi200074r98","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.3324\/haematol.2017.168732","article-title":"Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.","volume":"102","author":"Daver","year":"2017","journal-title":"Haematologica"},{"key":"coi200074r99","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2017.08.008","article-title":"Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: a retrospective cohort study.","volume":"61","author":"Frairia","year":"2017","journal-title":"Leuk Res"},{"issue":"1","key":"coi200074r100","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2017.285","article-title":"Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse.","volume":"32","author":"Boddu","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"coi200074r101","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hon.2488","article-title":"Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia.","volume":"36","author":"Lacombe","year":"2018","journal-title":"Hematol Oncol"},{"issue":"5","key":"coi200074r102","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3324\/haematol.2017.183525","article-title":"Clinical relevance of IDH1\/2 mutant allele burden during follow-up in acute myeloid leukemia: a study by the French ALFA group.","volume":"103","author":"Ferret","year":"2018","journal-title":"Haematologica"},{"issue":"10","key":"coi200074r103","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1038\/s41375-018-0086-0","article-title":"Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients.","volume":"32","author":"H\u00f6llein","year":"2018","journal-title":"Leukemia"},{"issue":"18","key":"coi200074r104","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2017.77.6757","article-title":"Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia.","volume":"36","author":"Morita","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi200074r105","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1038\/s41375-018-0158-1","article-title":"Response kinetics and factors predicting survival in core-binding factor leukemia.","volume":"32","author":"Boddu","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"coi200074r106","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3324\/haematol.2018.194712","article-title":"A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.","volume":"104","author":"Onecha","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"coi200074r107","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3324\/haematol.2018.191148","article-title":"Persistent IDH1\/2 mutations in remission can predict relapse in patients with acute myeloid leukemia.","volume":"104","author":"Ok","year":"2019","journal-title":"Haematologica"},{"issue":"20","key":"coi200074r108","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood-2012-11-468348","article-title":"MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial.","volume":"121","author":"Zhu","year":"2013","journal-title":"Blood"},{"issue":"12","key":"coi200074r109","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease.","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi200074r110","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.3324\/haematol.2011.044388","article-title":"Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse.","volume":"96","author":"Sockel","year":"2011","journal-title":"Haematologica"},{"issue":"3","key":"coi200074r111","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"issue":"12","key":"coi200074r112","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9","key":"coi200074r113","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/ajh.24782","article-title":"Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.","volume":"92","author":"Ragon","year":"2017","journal-title":"Am J Hematol"},{"issue":"14","key":"coi200074r114","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"coi200074r31","doi-asserted-by":"crossref","DOI":"10.1201\/b16018","volume-title":"Bayesian Data Analysis","author":"Gelman","year":"2013"},{"key":"coi200074r33","volume-title":"Introduction to Meta-analysis","author":"Borenstein","year":"2011"},{"key":"coi200074r34","author":"Fu","year":"2020"},{"key":"coi200074r32","doi-asserted-by":"crossref","unstructured":"Higgins? J, Thomas? J, Chandler? J,  Cochrane handbook for systematic reviews of interventions. Accessed September 1, 2019. http:\/\/www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2771199\/jamaoncology_short_2020_oi_200074_1606943486.31371.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T11:54:47Z","timestamp":1607601287000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2771199"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":114,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2020.4600","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,1]]}}}